Results 121 to 130 of about 56,178 (231)
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano +14 more
wiley +1 more source
Neuropsychiatric Disease and Treatment, 2008 Takahiko NagamineDivision of Psychiatric Internal Medicine, Seiwakai-Kitsunan Hospital, Suzenji, JapanAbstract: Second generation antipsychotics are associated with the risk of metabolic disorders such as diabetes mellitus and hyperlipidemia.
Takahiko Nagamine
doaj
A review of the aetiology and management of vocal behaviour in dementia [PDF]
, 2007 Vocal behaviour is a common form of agitation displayed by people with dementia. It refers to excessive screaming, abusive language, moaning, perseveration, and repetitive and inappropriate requests.
Abela, Stephen +2 more
core
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.We performed longitudinal evaluation using magnetic resonance imaging (MRI) and dopamine transporter single‐photon emission computed tomography (DAT‐SPECT) in a case of organophosphate‐induced toxic parkinsonism. Fluid‐attenuated inversion recovery (FLAIR) images showed bilateral striatal hyperintensity in the acute phase, followed by reduction of ...
Shuhei Nakao +6 more
wiley +1 more source
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi +2 more
wiley +1 more source
Future Journal of Pharmaceutical SciencesBackground Samidorphan is an opioid antagonist while Olanzapine is an effective medication for schizophrenia and bipolar disorder. A unique and accurate MS/HPLC approach due to simultaneous measurement of Olanzapine and Samidorphan is, therefore, more ...
Rambabu Kantipudi +1 more
doaj +1 more source
Involuntary Clozapine Treatment: A Systematic Review
Acta Psychiatrica Scandinavica, Volume 153, Issue 6, Page 595-609, June 2026.ABSTRACT Introduction We aimed to synthesize the information relevant for clinical practice on involuntary clozapine treatment. Methods Articles were identified with MEDLINE, Web of Sciences and PsycINFO search from inception through September 2025 (PROSPERO database registration CRD420251234475).
Hélène Verdoux +2 more
wiley +1 more source
Contact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli +8 more
wiley +1 more source
Gerodontology, Volume 43, Issue 2, Page 272-275, June 2026.ABSTRACT Introduction Burning mouth syndrome (BMS) is occasionally accompanied by denture intolerance. Case Presentation An 80‐year‐old woman with complaints of residual and relapsed intraoral pain and denture intolerance due to BMS was improved by olanzapine without severe adverse events, and her eating ability was successfully restored.
Motoko Watanabe +7 more
wiley +1 more source
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia
American Journal of Hematology, Volume 101, Issue 5, Page 1019-1024, May 2026.ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball +11 more
wiley +1 more source